CO5380014A1 - PHARMACEUTICAL FORMULATION FOR ORAL OR TOPIC ADMINISTRATION OF HYDROPHOBIC COMPOUNDS THAT DOES NOT FRAME EMULSION - Google Patents
PHARMACEUTICAL FORMULATION FOR ORAL OR TOPIC ADMINISTRATION OF HYDROPHOBIC COMPOUNDS THAT DOES NOT FRAME EMULSIONInfo
- Publication number
- CO5380014A1 CO5380014A1 CO00061955A CO00061955A CO5380014A1 CO 5380014 A1 CO5380014 A1 CO 5380014A1 CO 00061955 A CO00061955 A CO 00061955A CO 00061955 A CO00061955 A CO 00061955A CO 5380014 A1 CO5380014 A1 CO 5380014A1
- Authority
- CO
- Colombia
- Prior art keywords
- ch2or
- chor
- ch2o
- fatty acids
- oral
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 230000002209 hydrophobic effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000839 emulsion Substances 0.000 title 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 4
- 229930195729 fatty acid Natural products 0.000 abstract 4
- 239000000194 fatty acid Substances 0.000 abstract 4
- 150000004665 fatty acids Chemical class 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- -1 macrogol triglyceride glycerol esters Chemical class 0.000 abstract 2
- 229920000223 polyglycerol Polymers 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 125000005456 glyceride group Chemical group 0.000 abstract 1
- 229960003511 macrogol Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 abstract 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Epoxy Compounds (AREA)
Abstract
Un método para incrementar la viscosidad de una formulación farmacéutica para administración oral o tópica que comprende los pasos de combinar:a) una cantidad efectiva de uno o más ingredientes activos hidrofobicos; b) de 5 a 50% de uno o más compuestos seleccionados de esteres de poliglicerol o ácidos grasos de fórmula (1) CH2OR-CHOR-CH2O-[CH2CHOR-CH2O-]NCH2-CHOR-CH2OR (1)en donde n es un entero de 4 a 13 y R es H ó CO RAND#39 en donde RAND#39 es un alquilo hidroxilado saturado o insaturado de C8-22 y en donde por lo menos un grupo R no es hidrógeno;c) de 5 a 50% de uno o más compuestos seleccionado de ésteres de poliglicerol o ácidos grasos y/o ácidos grasos insaturado de fórmula (2) CH2OR-CHOR-CH2O-[CH2CHOR-CH2O-]NCH2-CHOR-CH2OR (2)en donde N es un entero de 0 a 10 y R es H ó COR" en donde R" es un alquilo hidroxilado saturado o insaturado de C8-22, y en donde mientras al menos un grupo R no es hidrógeno;d) de 5 a 50% de uno o más compuestos seleccionados de triglicerido de macrogol ésteres de glicerol, gliceridos parciales o ácidos grasos ó esteres de macrogol de ácidos grasos en los cuales la cantidad promedio de oxido de etileno reaccionado en la síntesis de estas sustancias varia desde 50 a 150 moles y constantemente la proporción entre los componentes b) y d) es desde 0,1:1 hasta 10:1;en donde los anteriores porcentajes son seleccionados de un total del 100%;y donde después de la disolución con agua 1:1 en volumen la viscosidad de la disolución se incrementa hasta por lo menos 5 veces en comparación con la composición sin diluir.A method for increasing the viscosity of a pharmaceutical formulation for oral or topical administration comprising the steps of combining: a) an effective amount of one or more hydrophobic active ingredients; b) 5 to 50% of one or more compounds selected from polyglycerol esters or fatty acids of formula (1) CH2OR-CHOR-CH2O- [CH2CHOR-CH2O-] NCH2-CHOR-CH2OR (1) where n is a integer from 4 to 13 and R is H or CO RAND # 39 where RAND # 39 is a saturated or unsaturated hydroxylated alkyl of C8-22 and where at least one group R is not hydrogen; c) from 5 to 50% of one or more compounds selected from polyglycerol esters or fatty acids and / or unsaturated fatty acids of formula (2) CH2OR-CHOR-CH2O- [CH2CHOR-CH2O-] NCH2-CHOR-CH2OR (2) wherein N is an integer from 0 to 10 and R is H or COR "where R" is a saturated or unsaturated hydroxylated alkyl of C8-22, and where while at least one group R is not hydrogen; d) from 5 to 50% of one or more compounds selected from macrogol triglyceride glycerol esters, partial glycerides or fatty acids or fatty acid macrogol esters in which the average amount of ethylene oxide reacted in the synthesis of these substances s varies from 50 to 150 moles and constantly the ratio between components b) and d) is from 0.1: 1 to 10: 1; where the above percentages are selected from a total of 100%; and where after dissolution With 1: 1 volume water, the viscosity of the solution increases up to at least 5 times compared to the undiluted composition.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9919288A GB2355656B (en) | 1999-08-17 | 1999-08-17 | Pharmaceutical compositions for oral and topical administration |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5380014A1 true CO5380014A1 (en) | 2004-03-31 |
Family
ID=10859192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00061955A CO5380014A1 (en) | 1999-08-17 | 2000-08-17 | PHARMACEUTICAL FORMULATION FOR ORAL OR TOPIC ADMINISTRATION OF HYDROPHOBIC COMPOUNDS THAT DOES NOT FRAME EMULSION |
Country Status (40)
| Country | Link |
|---|---|
| US (1) | US20070190132A1 (en) |
| EP (2) | EP1334717B1 (en) |
| JP (2) | JP2003507343A (en) |
| KR (2) | KR100828748B1 (en) |
| CN (2) | CN1382061A (en) |
| AR (2) | AR025324A1 (en) |
| AT (2) | ATE402691T1 (en) |
| AU (1) | AU777740B2 (en) |
| BR (1) | BR0013385A (en) |
| CA (2) | CA2380951C (en) |
| CO (1) | CO5380014A1 (en) |
| CY (1) | CY1105318T1 (en) |
| CZ (2) | CZ296591B6 (en) |
| DE (2) | DE60018081T2 (en) |
| DK (2) | DK1210119T3 (en) |
| EE (2) | EE04955B1 (en) |
| EG (1) | EG23994A (en) |
| ES (2) | ES2237443T3 (en) |
| GB (1) | GB2355656B (en) |
| HK (1) | HK1049629A1 (en) |
| HR (1) | HRP20020154B1 (en) |
| HU (1) | HUP0203236A3 (en) |
| IL (4) | IL148200A0 (en) |
| JO (1) | JO2324B1 (en) |
| MX (1) | MXPA02001631A (en) |
| NO (2) | NO20020760L (en) |
| NZ (1) | NZ517271A (en) |
| PE (1) | PE20010636A1 (en) |
| PL (1) | PL192769B1 (en) |
| PT (2) | PT1210119E (en) |
| RU (2) | RU2279894C2 (en) |
| SA (1) | SA00210487B1 (en) |
| SG (1) | SG143019A1 (en) |
| SI (1) | SI1210119T1 (en) |
| SK (2) | SK286083B6 (en) |
| TN (1) | TNSN00173A1 (en) |
| UA (2) | UA72539C2 (en) |
| UY (1) | UY26303A1 (en) |
| WO (1) | WO2001012229A1 (en) |
| ZA (2) | ZA200308221B (en) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2355656B (en) * | 1999-08-17 | 2004-04-07 | Galena As | Pharmaceutical compositions for oral and topical administration |
| FR2826261B1 (en) * | 2001-06-26 | 2005-03-25 | Lmd | TOPICAL COMPOSITION COMPRISING A CYTOTOXIC PRODUCT AND ITS USE IN THE TREATMENT OF ALOPECHE |
| DE10154464B4 (en) * | 2001-11-08 | 2005-10-20 | Max Delbrueck Centrum | Orally administrable pharmaceutical preparation comprising liposomally encapsulated taxol |
| KR20030065831A (en) * | 2002-02-01 | 2003-08-09 | 주식회사 태평양 | cyclosporin-containing sustained release pharmaceutical composition |
| US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
| US9101540B2 (en) | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
| EP1935407A1 (en) * | 2002-12-03 | 2008-06-25 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
| CN100337620C (en) * | 2002-12-04 | 2007-09-19 | 日清药业股份有限公司 | Water-soluble composition containing coenzyme q10 |
| JP4518042B2 (en) * | 2002-12-04 | 2010-08-04 | 日油株式会社 | Method for producing water-soluble composition containing coenzyme Q10 |
| KR20200083657A (en) * | 2002-12-09 | 2020-07-08 | 아브락시스 바이오사이언스, 엘엘씨 | Compositions and methods of delivery of pharmacological agents |
| US6979672B2 (en) * | 2002-12-20 | 2005-12-27 | Polichem, S.A. | Cyclosporin-based pharmaceutical compositions |
| TW200616681A (en) * | 2004-10-05 | 2006-06-01 | Recordati Ireland Ltd | Lercanidipine capsules |
| EP1806125B1 (en) * | 2004-10-20 | 2011-08-03 | Kao Corporation | Liquid compositions for oral cavity |
| KR20080003322A (en) * | 2005-02-24 | 2008-01-07 | 엘란 파마 인터내셔널 리미티드 | Nanoparticle Blend of Docetaxel and Analogs thereof |
| WO2010060798A1 (en) * | 2008-11-28 | 2010-06-03 | Advance Holdings Limited | Pharmaceutical formulation comprising diclofenac and a hydroxy fatty acid polyoxyalkylene ester |
| BRPI1008983A2 (en) * | 2009-03-12 | 2016-03-22 | Advance Holdings Ltd | pharmaceutical formulation |
| KR101100933B1 (en) * | 2009-04-23 | 2012-01-02 | 한국기술교육대학교 산학협력단 | Solder ball remover |
| EP3274054A1 (en) | 2015-03-27 | 2018-01-31 | Arch Personal Care Products, L.P. | Viscosity building composition for personal care products |
| CN112426403B (en) * | 2020-12-09 | 2021-09-17 | 南京天纵易康生物科技股份有限公司 | Oral ulcer gel and preparation method and application thereof |
| US20250186542A1 (en) * | 2022-05-02 | 2025-06-12 | Chugai Seiyaku Kabushiki Kaisha | Composition containing peptide compound for use with surfactant |
| CN119770478B (en) * | 2024-12-31 | 2025-12-19 | 美济生物医药(广州)有限公司 | Paclitaxel oral pharmaceutical composition, preparation method and application thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2222770B (en) * | 1988-09-16 | 1992-07-29 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporins |
| US6007840A (en) * | 1988-09-16 | 1999-12-28 | Novartis Ag | Pharmaceutical compositions comprising cyclosporins |
| US5342625A (en) * | 1988-09-16 | 1994-08-30 | Sandoz Ltd. | Pharmaceutical compositions comprising cyclosporins |
| CZ288631B6 (en) * | 1996-01-18 | 2001-08-15 | Galena, A. S. | Therapeutic preparations containing cyclosporin |
| CZ288739B6 (en) * | 1996-08-01 | 2001-08-15 | Galena, A. S. | Cyclosporin containing medicinal preparations |
| CZ267796A3 (en) * | 1996-09-12 | 1998-04-15 | Galena A.S. | Medicamentous preparations, particularly for internal application in the form of inherently micro-emulsifying therapeutical systems |
| EP0973502A1 (en) * | 1997-03-12 | 2000-01-26 | Abbott Laboratories | Lipophilic binary systems for the administration of lipophilic compounds |
| DK0969856T3 (en) * | 1997-03-12 | 2005-05-02 | Abbott Lab | Hydrophilic binary systems for the administration of cyclosporine |
| AU728698B2 (en) * | 1997-07-29 | 2001-01-18 | Boehringer Ingelheim International Gmbh | Self-emulsifying formulation for lipophilic compounds |
| US6063762A (en) * | 1997-12-05 | 2000-05-16 | Chong Kun Dang Corp. | Cyclosporin-containing microemulsion preconcentrate composition |
| US20030216303A1 (en) * | 1998-03-06 | 2003-11-20 | Michael Ambuhl | Emulsion preconcentrates containing cyclosporin or a macrolide |
| GB2355656B (en) * | 1999-08-17 | 2004-04-07 | Galena As | Pharmaceutical compositions for oral and topical administration |
-
1999
- 1999-08-17 GB GB9919288A patent/GB2355656B/en not_active Revoked
-
2000
- 2000-08-17 MX MXPA02001631A patent/MXPA02001631A/en active IP Right Grant
- 2000-08-17 DK DK00951765T patent/DK1210119T3/en active
- 2000-08-17 EP EP03008447A patent/EP1334717B1/en not_active Expired - Lifetime
- 2000-08-17 AT AT03008447T patent/ATE402691T1/en active
- 2000-08-17 JP JP2001516572A patent/JP2003507343A/en active Pending
- 2000-08-17 HK HK03101840.7A patent/HK1049629A1/en unknown
- 2000-08-17 CZ CZ20032302A patent/CZ296591B6/en not_active IP Right Cessation
- 2000-08-17 UA UA2002032078A patent/UA72539C2/en unknown
- 2000-08-17 ES ES00951765T patent/ES2237443T3/en not_active Expired - Lifetime
- 2000-08-17 IL IL14820000A patent/IL148200A0/en active IP Right Grant
- 2000-08-17 CA CA2380951A patent/CA2380951C/en not_active Expired - Fee Related
- 2000-08-17 CA CA002452118A patent/CA2452118A1/en not_active Abandoned
- 2000-08-17 EE EEP200300371A patent/EE04955B1/en not_active IP Right Cessation
- 2000-08-17 WO PCT/GB2000/003161 patent/WO2001012229A1/en not_active Ceased
- 2000-08-17 RU RU2002106825/15A patent/RU2279894C2/en not_active IP Right Cessation
- 2000-08-17 SK SK1023-2003A patent/SK286083B6/en not_active IP Right Cessation
- 2000-08-17 KR KR1020057015114A patent/KR100828748B1/en not_active Expired - Fee Related
- 2000-08-17 CZ CZ20020575A patent/CZ296170B6/en not_active IP Right Cessation
- 2000-08-17 PE PE2000000842A patent/PE20010636A1/en not_active Application Discontinuation
- 2000-08-17 BR BR0013385-0A patent/BR0013385A/en not_active Application Discontinuation
- 2000-08-17 EP EP00951765A patent/EP1210119B1/en not_active Expired - Lifetime
- 2000-08-17 ZA ZA200308221A patent/ZA200308221B/en unknown
- 2000-08-17 DK DK03008447T patent/DK1334717T3/en active
- 2000-08-17 UY UY26303A patent/UY26303A1/en not_active Application Discontinuation
- 2000-08-17 KR KR1020027002109A patent/KR100828747B1/en not_active Expired - Fee Related
- 2000-08-17 DE DE60018081T patent/DE60018081T2/en not_active Expired - Lifetime
- 2000-08-17 AT AT00951765T patent/ATE288766T1/en active
- 2000-08-17 TN TNTNSN00173A patent/TNSN00173A1/en unknown
- 2000-08-17 PT PT00951765T patent/PT1210119E/en unknown
- 2000-08-17 AU AU64613/00A patent/AU777740B2/en not_active Ceased
- 2000-08-17 CO CO00061955A patent/CO5380014A1/en not_active Application Discontinuation
- 2000-08-17 PL PL353445A patent/PL192769B1/en unknown
- 2000-08-17 HR HR20020154A patent/HRP20020154B1/en not_active IP Right Cessation
- 2000-08-17 EE EEP200200075A patent/EE04954B1/en not_active IP Right Cessation
- 2000-08-17 SK SK248-2002A patent/SK2482002A3/en unknown
- 2000-08-17 ES ES03008447T patent/ES2311077T3/en not_active Expired - Lifetime
- 2000-08-17 SI SI200030614T patent/SI1210119T1/en unknown
- 2000-08-17 CN CN00813185A patent/CN1382061A/en active Pending
- 2000-08-17 CN CNA2008101094369A patent/CN101406453A/en active Pending
- 2000-08-17 SG SG200305899-7A patent/SG143019A1/en unknown
- 2000-08-17 HU HU0203236A patent/HUP0203236A3/en unknown
- 2000-08-17 IL IL15810800A patent/IL158108A0/en unknown
- 2000-08-17 JO JO2000302A patent/JO2324B1/en active
- 2000-08-17 NZ NZ517271A patent/NZ517271A/en unknown
- 2000-08-18 AR ARP000104281A patent/AR025324A1/en unknown
- 2000-08-19 EG EG20001069A patent/EG23994A/en active
- 2000-11-01 SA SA00210487A patent/SA00210487B1/en unknown
-
2002
- 2002-02-15 ZA ZA200201315A patent/ZA200201315B/en unknown
- 2002-02-15 NO NO20020760A patent/NO20020760L/en not_active Application Discontinuation
- 2002-02-17 IL IL148200A patent/IL148200A/en not_active IP Right Cessation
- 2002-02-17 IL IL158108A patent/IL158108A/en not_active IP Right Cessation
-
2003
- 2003-04-26 PT PT03008447T patent/PT1334717E/en unknown
- 2003-08-17 DE DE60322454T patent/DE60322454D1/en not_active Expired - Lifetime
- 2003-09-10 AR ARP030103268A patent/AR043106A2/en unknown
- 2003-10-24 NO NO20034778A patent/NO20034778D0/en not_active Application Discontinuation
- 2003-11-17 RU RU2003133451/15A patent/RU2279895C2/en not_active IP Right Cessation
- 2003-12-24 UA UA20031212327A patent/UA75926C2/en unknown
-
2004
- 2004-03-31 JP JP2004106963A patent/JP2004238399A/en active Pending
-
2005
- 2005-05-05 CY CY20051100574T patent/CY1105318T1/en unknown
-
2007
- 2007-04-13 US US11/786,846 patent/US20070190132A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5380014A1 (en) | PHARMACEUTICAL FORMULATION FOR ORAL OR TOPIC ADMINISTRATION OF HYDROPHOBIC COMPOUNDS THAT DOES NOT FRAME EMULSION | |
| RU2496467C2 (en) | Compositions applicable for dental whitening | |
| DK1173153T3 (en) | Oral pharmaceutical preparations containing long chain triglycerides and lipophilic surfactants | |
| UY27320A1 (en) | NEW PHARMACEUTICAL COMPOSITIONS | |
| GB399917A (en) | Improvements in preparations for the care of the teeth and mouth | |
| AR017801A1 (en) | A COMPOSITION OF PRE-CONCENTRATED IN MICROEMULSION CONTAINING CYCLOSPORIN, AND A PHARMACEUTICAL FORMULATION THAT UNDERSTANDS | |
| RU2002106825A (en) | PHARMACEUTICAL COMPOSITIONS FOR ORAL AND LOCAL USE | |
| JPS6115815A (en) | hair cosmetics | |
| RU2008134492A (en) | PHARMACEUTICAL COMPOSITION CONTAINING A BICYCLIC COMPOUND AND METHOD FOR STABILIZING A Bicyclic Compound | |
| ES461020A1 (en) | Organic compounds | |
| FR2850019B1 (en) | CLEANING COMPOSITIONS READY FOR USE, PREPARATION METHOD AND DECOLORATION PROCESS | |
| JP2608777B2 (en) | Whitening cosmetics | |
| EP0560322A1 (en) | Detergent composition | |
| JP4118793B2 (en) | Hair bleaching agent composition | |
| KR20230116911A (en) | Treatment regimen of onychomycosis using allylamine antifungal compositions | |
| JP2594553B2 (en) | Hair cosmetics | |
| RU2018129304A (en) | NEW IMPROVED COMPOSITION CONTAINING AT LEAST ONE FRAME | |
| JPH09175936A (en) | Cleansing composition | |
| JPS5764609A (en) | Cyclophosphamide composition for rectal administration | |
| KR101461640B1 (en) | Oxidative liquid hair dye composition | |
| JP2016121079A (en) | Dye remover | |
| UY28008A1 (en) | PHARMACEUTICAL COMPOSITIONS FOR ORAL AND TOPICAL ADMINISTRATION | |
| JP2023097396A (en) | Keratin plug decomposition accelerator | |
| ES8503947A1 (en) | Antimycotic Agent With a High Release of Active Compounds, in the Form of a Cream | |
| JPS5740415A (en) | Novel active type vitamin d3 derivative composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Application granted | ||
| FD | Application lapsed |